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Abstract
Hereditary haemorrhagic telangiectasia (HHT) is a multisystemic vascular dysplasia that leads to nosebleeds, anaemia due
to blood loss, and arteriovenous malformations (AVMs) in organs such as the lungs, liver and brain. HHT is estimated to
affect 85,000 European citizens, but most health care providers have limited prior HHT exposure or training.
Outcome Measures were developed and implemented by the HHT Working Group of the European Reference Network
for Rare Vascular Diseases (VASCERN), in order to maximise the number of patients receiving good care. The measures
specifically target areas where optimal management reduces morbidity and mortality in HHT patients, and were designed
to be robust to emerging new evidence. Thresholds are the percentage of patients in particular settings who have been
recommended screening, or provided with written advice. The 5 Outcome Measures cover (1) pulmonary AVM screening;
(2) written nosebleed advice, (3) assessment of iron deficiency; (4) antibiotic prophylaxis prior to dental and surgical
procedures for patients with pulmonary AVMs, and (5) written advice on pregnancy. They are not a blueprint
for detailed HHT management, but are suitable for all clinicians to be aware of and implement.
In summary, these 5 Outcome Measures provide metrics to identify healthcare providers of good care, and
encourage care improvement by all healthcare providers.
Keywords: Anaemia, Antibiotic prophylaxis, Epistaxis, Iron deficiency, Nosebleeds, Pulmonary arteriovenous
malformations, Pregnancy
Background
Development and implementation of Outcomes Measures
are an effective part of Quality and Safety Frameworks
that lead to Service Improvements. More specifically, if
the Outcome Measures are carefully selected, their
dissemination and implementation can directly improve
patient care, including that from health care providers
with limited prior exposure or training on the specific dis-
ease. Therefore simple, clinical practice-based Outcome
Measures are particularly important for rare multisystemic
conditions.
The current statement refers to one specific rare disease,
hereditary haemorrhagic telangiectasia (HHT; Online
Mendelian Inheritance in Man® #187300), which is a mul-
tisystemic vascular dysplasia that leads to telangiectasia
and arteriovenous malformations (AVMs) in visceral and
mucocutanous vascular beds [1]. Based on a conservative
population prevalence of 1 in 6000 [2–4], HHT is esti-
mated to affect approximately 85,000 European citizens.
The main goal of management is to maximise the number
of affected individuals receiving safe and effective pre-
ventative strategies in order to limit the number and
severity of HHT complications. The reason this is
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important, is that where optimal management is insti-
tuted, previously reduced life expectancy [3, 5–7] may
improve to that of the general population, [8] early
strokes, brain abscess, maternal deaths and migraines
are prevented, [9–11] nosebleeds are reduced, [12–17]
and patients receive timely treatments for iron defi-
ciency anaemia and other complications.
HHT can be diagnosed either clinically using the
Curaçao criteria [1] (Table 1), or through a molecular
gene test. A patient with definite HHT will have at least
3 of the 4 Curaçao Criteria, or a pathogenic sequence
variant in ENG, ACVRL1 or SMAD4. Identification of
pulmonary arteriovenous malformations (PAVMs) is rec-
ommended for all HHT patients because PAVMs com-
monly cause preventable complications in asymptomatic
patients [18, 19]. Risk-benefit analyses in asymptomatic
individuals are more complex for other AVMs where
screening is more controversial [20], limited to specific
subpopulations, or not recommended [21].
Main text
Outcome Measures have been embedded within the
Operational Criteria of the new European Reference
Networks (ERNs) for Rare Diseases [22]. The HHT Out-
come Measures were developed and implemented by the
HHT Working Group of the ERN for Rare Vascular
Diseases (VASCERN), [23] in order to maximise the
number of patients receiving good care. Details of how
the topics were selected and developed into Outcome
Measures are provided in the Additional file 1.
Following on from an established diagnosis of HHT or
PAVMs, the outcome measure thresholds are the per-
centage of adult patients in particular settings who have
been recommended screening, or provided with written
advice (Table 2). These will be met easily by best prac-
tice in HHT centres of excellence, but may not be
achieved in general specialty care. The current
manuscript refers only to the principles of manage-
ment- details of management lie outside of the scope
of this manuscript.
Measure 1
At least 90% of definite HHT patients will have a screen for
pulmonary arteriovenous malformations (PAVMs)
As stated elsewhere [18, 19], all HHT patients should be
offered a screen for PAVMs in adult life. The screen and
subsequent management may require cross-specialist
referral. Screening should be repeated after pregnan-
cies. Where a childhood screening test has been per-
formed, screening should be repeated after the patient
is fully grown.
HHT-associated PAVMs affect approximately 50% of
HHT patients i.e. 40,000 Europeans. Recent European
data suggest that untreated, 6–8% may develop a cere-
bral abscess (usually with fatal or life-changing conse-
quences [24–26]), at least 10–12% an early ischaemic
stroke, and 1% of pregnancies will result in maternal
death. Diagnosed patients can benefit from stroke
reduction strategies, particularly embolization therapy to
obliterate PAVMs [9, 27, 28], antibiotic prophylaxis to
prevent cerebral and visceral abscesses from silent bac-
teraemia (see Measure 4), and pregnancy management
associated with a statistically improved survival rate in
the event of a life-threatening complication [10].
A PAVM screen should be considered in all adult
HHT patients. However the 90% threshold takes into ac-
count the facts that not all HHT patients choose to take
up the option of PAVM screening, and there may also
be competing clinical circumstances which render the
discussion of screening inappropriate at the time of the
clinical review. Overall, the Outcome Measure ensures
that the possibility of PAVMs is remembered and ad-
dressed for all HHT patients, irrespective of their pres-
entation pattern.
Measure 2
At least 90% of definite HHT patients will have received
nosebleed advice in writing
Nosebleeds (epistaxis) affect > 90% of HHT patients,
may be the presenting symptom of HHT, but may not
be volunteered by patients unless specifically asked.
HHT nosebleeds often occur daily, lasting many minutes
and even hours: It is poorly appreciated that severe re-
current HHT nosebleeds can generate acute haemo-
dynamic compromise and/or chronic cardiac failure in
addition to iron deficiency anaemia.
A nosebleed history is to be evaluated for all HHT pa-
tients. The 90% threshold for written advice takes into
account the facts that not all HHT patients have nose-
bleeds at any given time, though these may develop in
the future, and the information can be important for
family members also affected by HHT.
Overall, this measure ensures that irrespective of the pa-
tient’s presentation pattern, epistaxis is not overlooked,
Table 1 The Curaçao Criteria
1. Epistaxis: spontaneous, recurrent nose bleeds
2. Telangiectases: multiple, at characteristic sites (lips, oral cavity,
fingers, nose)
3. Visceral lesions such as gastrointestinal telangiectasia (with or without
bleeding); pulmonary AVM; hepatic AVM; cerebral AVM; spinal AVM
4. Family history: a first degree relative with HHT according to these criteria
The HHT diagnosis is definite if 3 criteria are present, possible or suspected
if 2 criteria are present, and unlikely if fewer than 2 criteria are present. A
pathogenic (null) sequence variant in ENG, ACVRL1 or SMAD4 also defines
definite clinical HHT according to current understanding. A negative HHT
gene test does not exclude HHT unless the gene variant causing HHT has
been identified in another affected family member
Shovlin et al. Orphanet Journal of Rare Diseases  (2018) 13:136 Page 2 of 5
and practical information is provided to reduce the sever-
ity of epistaxis, and its sequelae.
Measure 3
At least 70% of definite HHT patients will have an assessment
of iron deficiency at each consultation
Iron deficiency affects > 60% of all HHT patients (i.e. >
50,000 Europeans with HHT), and leads to anaemia
(higher likelihood of blood transfusions), malaise, sub-
optimal immune, skeletal muscle and thyroid function;
prematurity, poor maternal and perinatal outcomes in
pregnancy; and impaired motor and cognitive develop-
ment in children. In HHT patients, iron deficiency leads
to angina and tachycardia, aggravates high output car-
diac failure, and is associated with venous thromboem-
boli (VTE), and ischaemic strokes.
Generally, anaemia is defined by low haemoglobin, and
iron deficiency is confirmed to be present when the ferritin
is sub-normal [29, 30]. As stated elsewhere however [31], in
HHT, not all iron deficient patients have low haemoglobin
since many patients have hypoxaemia due to pulmonary
AVMs and need higher than normal haemoglobin to com-
pensate. Similarly, a normal or high ferritin does not reli-
ably exclude iron deficiency as it is an acute phase marker
and may be supra-normal when serum iron, transferrin sat-
uration index and red cell indices such as MCV or MCH/
MCHC demonstrate iron deficient pictures [30].
Iron deficiency is commonly indolent and not appreci-
ated by the patient until after correction. This measure
ensures that irrespective of the patient’s presentation
pattern, iron deficiency is promptly identified, enabling
optimal management.
Measure 4
100% of patients with PAVMs will have written advice on
antibiotics prior to dental and surgical procedures
This measure is recommended to reduce the rate of cere-
bral abscess which occurred in 6–8% of referrals to
current European centres, usually resulting in substantial
morbidity, and health care burdens [24–26]. Despite anti-
biotic prophylaxis being a long-standing recommendation
for PAVM patients, in 2017, only 2/25 (8%) consecutive
referrals to a UK centre for PAVM embolization had been
advised to use prophylactic antibiotics.
The majority of cerebral abscesses in HHT/PAVM pa-
tients are associated with periodontal microbes, and/or
precipitating dental and other interventional events that
normally lead to transient bacteraemias, i.e. prior to
non-sterile invasive procedures (such as dental, endo-
scopic, and surgical). In the general population, the bac-
teraemias are cleared (in terms of positive cultures)
within minutes in the absence of antibiotics, but pre-
vented or resolved earlier with prior antibiotic adminis-
tration. [32] Good dental care is also important.
Written management advice to all PAVM patients is
anticipated to ensure patients are aware and can com-
municate to all relevant practitioners, to address the
current situation where patients may be refused prophy-
laxis and go on to develop a cerebral abscess [26].
Measure 5
100% of pregnant women with PAVMs identified by CT scan/
imaging will be provided with written advice on PAVM/HHT
pregnancies
Although the majority of PAVM pregnancies proceed
normally, there is a 1% risk of maternal death in preg-
nancy that can be reduced by prior awareness. Precise
content will vary by country according to obstetric care
pathways but may include alerts regarding potential red
flag symptoms demanding immediate hospital admission
(haemoptysis, sudden acute breathlessness), antibiotic
prophylaxis at delivery, and management as “high-risk”
pregnancies involving a multiprofessional approach.
Conclusion
These five Outcome Measures provide metrics to identify
healthcare providers of good care, encourage care improve-
ment by all healthcare providers, and should be robust to
emerging new evidence. They are not a blueprint for de-
tailed HHT management, but are suitable for all clinicians
to be aware of and implement. For the latest information,
please see documents on the VASCERN website [23].
Table 2 HHT outcome measures
Target Population Estimated cases in Europe Measure Target threshold
Measure 1} All HHT- clinical or molecular
diagnosis
85,000 Screen for pulmonary AVMs ≥ 90%
Measure 2} Receive nosebleed advice in writing ≥ 90%
Measure 3} Assessment of iron deficiency at each consultation ≥ 70%
Measure 4 Pulmonary AVMs (+/− HHTa) 196,000 Receive written advice on antibiotic prophylaxis
prior to dental and surgical procedures
100%
Measure 5 Pregnant women with pulmonary
AVMs (+/− HHTa)
~ 1000 Receive written advice on PAVM/HHT pregnancies 100%
Prevalence estimates assume a European population of 510,000,000 (196,000 with HHT or PAVMs), 100,000 females with HHT or PAVMs; and an average of 1.6
children per woman accounting for 1.2 years pregnant in 84 years life expectancy. aPulmonary AVMs also occur outside HHT and are estimated to affect 1 in 2600
people [33]. HHT and non HHT-related pulmonary AVMs are currently managed in the same way
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